The Global Secondary Hyperparathyroidism Treatment Market is expected to reaching USD 7282.20 million by 2025


 

Secondary hyperparathyroidism is a disease of the parathyroid glands that causes an increase in the production of parathyroid hormone (PTH) to maintain normal calcium levels in the blood. The disease is caused by an underlying chronic kidney disease in which the kidneys do not clean the phosphorus in the blood. The excess phosphorus in the blood causes a drop in calcium levels, resulting in secondary hyperparathyroidism. PTH levels are high in the early stages of secondary hyperparathyroidism, but calcium levels are low or normal. High PTH levels cause cardiovascular complications, low blood count, abnormal fat and sugar metabolism, bone weakness, and calciphylaxis. Secondary hyperparathyroidism can also be caused by vitamin D deficiency, vitamin D-resistant rickets, high abnormal magnesium levels, malnutrition, and gastrointestinal malabsorption syndrome.

One of the primary reasons for the growth of the secondary hyperparathyroidism treatment market is an increase in the prevalence of chronic kidney disease, which is a leading cause of secondary hyperparathyroidism. Furthermore, an increase in disease-related research activities and product approvals contribute to market growth. For example, Amgen's Parsabiv (etelcalcetide) was approved in Europe in 2016 for the treatment of secondary hyperparathyroidism in adult patients on hemodialysis with chronic kidney disease. Furthermore, the increasing number of products in the pipeline drives market expansion. However, the side effects of secondary hyperparathyroidism treatment, such as diarrhea, vomiting, muscle spasms, and a drop in serum calcium, may hurt the market. Furthermore, the treatment causes a decrease in serum calcium levels, which increases the risk of heart failure due to hypotension and decreased myocardial performance.

The global Secondary Hyperparathyroidism Treatment Market is expected to grow to USD 4471.4 million by 2027, up from USD 3143.6 million in 2020, at a CAGR of 5.1 percent between 2021 and 2027.

The market for secondary hyperparathyroidism, treatment can be divided into three categories: treatment type, distribution channel, and geography. The market can be divided into two categories based on treatment type: surgery and drug class. Vitamin D and derivatives, calcimimetics, and phosphate binders are subclasses of this drug class. Calcimimetics, a drug class, are expected to grow significantly due to their ability to bind to parathyroid cell receptors and decrease the level of calcium in blood serum. Furthermore, the increasing product approvals of calcimimetics contribute to the segment's rapid growth. The market can be divided into two categories based on distribution channels: hospital pharmacies and retail pharmacies.

Geographically, the market for secondary hyperparathyroidism treatment is divided into North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. The secondary hyperparathyroidism treatment market is expected to be dominated by North America. This can be attributed to a well-developed health-care infrastructure, increased public awareness, and favorable economic conditions. This can be attributed to well-developed healthcare infrastructure, increased public awareness, and favorable reimbursement scenarios. Europe is expected to be the market's lagging next region. However, the region's market growth is expected to be hampered by sluggish economic growth.

Amgen Inc., OPKO Health, Inc., AbbVie Inc., Shire Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc, KAI Pharmaceuticals, Leo Pharma A/S and Deltanoid Pharmaceuticals are the market leaders in secondary hyperparathyroidism treatment.

Comments

Post a Comment

Popular posts from this blog

Quaternary Ammonium Compounds Market to Grow at USD 1.63 billion by 2027: COVID Impact & Post COVID Analysis, Business Opportunities, and Strategies

Image
  By 2027, the global market for Quats (Quaternary Ammonium Compounds) is expected to reach USD 1.63 billion. The market is being driven by the rise in the occurrence of hospital-acquired infections (HAIs) and the implementation of stringent regulations and favorable government initiatives on disinfection and sterilization. Developing economies are expected to give significant opportunities for growth. Fabric softeners, disinfectants, surfactants, antistatic agents, and wood preservation are just a few of the uses for quaternary ammonium compounds. The product's numerous applications are projected to raise demand shortly. Quaternary ammonium compounds are commonly employed as conditioning agents in personal care products, such as skin, textile, and hair softeners. The surfactant industry considers QACs to be the ultimate workhorse. They're on the USEPA's "High Production Volume Chemicals" list. Self-assembly, surface-active properties, detergency, and antibact...
Read more

Butyraldehyde Market Trends, Growth, Demand, opportunities, Scope & Forecast 2027 by CMI

Image
  Buthylaldehyde (also known as butanal) is a 4-carbon aldehyde that is used as a building block in organic syntheses to make various products such as n-butanol, 2-ethyl hexanol, 2-ethyl hexanoic acid, trimethylolpropane, and polyvinyl butyral. Pharmaceuticals, agrochemicals, antioxidants, textile auxiliaries, perfumes, flavors, and many forms of additives are all made with it as an intermediate (fillers, wetting agents, defoaming agents, improvers). Alcohols (mono- and multi-hydroxide), acids, amines, and esters are all made from N-butyraldehyde as a raw material. Rubber accelerators, synthetic resins, plasticizers, solvents, and high molecular weight polymers are the biggest uses of butyraldehyde. All of these buthylaldehyde applications are detailed in this study. Butyraldehyde is widely used as a starting material for the downstream organic synthesis of n-butanol, trimethylolpropane, 2-ethyl hexanoic acid, and polyvinyl butyral. Pharmaceutical intermediates, synthetic resins,...
Read more

Glass Mat Thermoplastic Market : Size, Growth, Regional Analysis, And Market Area

Image
Glass mat thermoplastic is a thermoplastic that can be easily moulded and is used to make a variety of components, primarily in the automotive industry. Because of the longer residual length of the glass strands, glass mat thermoplastic has better mechanical properties than injection moulded reinforced thermoplastic. It is primarily used as a replacement for steel and aluminium. They are available in panel form as well as 3D structural component form. Furthermore, they are a lightweight material with a low relative density, excellent hardness and rigidity at low temperatures, and are chemical and moisture resistant . These are durable materials with ease of recyclability. Furthermore, the demand for the glass mat thermoplastic material from the automobile and aeration industries leads to market growth. When compared to other end-use industries, the automotive application segment is expected to remain the largest. Furthermore, a surge in government initiatives for increased fuel eco...
Read more